STOCKHOLM--(BUSINESS WIRE)--SciBase (STO:SCIB), who in June of this year took over the manufacturing
of their single-use electrode from Ginolis, has appointed Anna Danström
as Supply Chain & Production Manager. Anna Danström, who previously was
responsible for electrode development at SciBase, has recently assumed
her new role. As Supply Chain & Production Manager Anna becomes a member
of the management team, where she replaces Marko Päivärinne.
The insourcing of manufacturing has resulted in a number of advantages
for SciBase, including better conditions to pursue the development of
more cost-effective larger-scale manufacturing. With Anna as new Supply
Chain & Production Manager the work to streamline and scale the
production of electrodes in Uppsala will be intensified.
- The manufacturing of electrodes is our most strategically important
process and it is of utmost importance that we can both streamline and
increase production capacity going forward, a task which Anna is
perfectly suited for. With the addition of Anna and also Niklas
Jakobsson, who recently assumed responsibility for Quality Assurance and
Regulatory issues, we are creating a very strong management team with
the relevant competence and experience, says Simon Grant, CEO of SciBase.
Apart from being responsible for the development of electrodes at
SciBase Anna has had long experience within medtech, working for a
number of international companies such as St. Jude Medicals where she
worked in a number of global technology transfer projects. Anna also has
experience in working with FDA-related processes, which will be a
benefit given SciBase’s on-going PMA process and the forthcoming launch
on the US market. Anna replaces Marko Päivärinne who has decided to
pursue new challenges outside the company from early next year.
SciBase’s product Nevisense requires a new electrode for every patient
examined. SciBase’s business model is based on selling instruments, but
the major potential lies in the continuous use of the instruments, which
generates revenues from the sale of the single-use electrodes. During
the autumn SciBase passed a milestone of 10,000 electrodes sold during
the year and increased sales of the electrodes by 77 percent for the
first nine months of the year.
For further information please visit www.scibase.com
This information is information that SciBase Holding AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact person
set out above, at 08.00 CET on December 1, 2016.
About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting
for nearly half of all cancers. It has been estimated that nearly half
of all Americans who live to the age of 65 will develop skin cancer at
least once. Malignant melanoma is the most fatal form of skin cancer
causing the majority (75%) of deaths related to skin cancer. Worldwide,
doctors diagnose about 230,000 new cases of melanoma yearly.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in
Stockholm that has developed a unique point-of-care device for the
accurate detection of malignant melanoma. Its product, Nevisense, helps
doctors to detect malignant melanoma, the most dangerous type of skin
cancer. SciBase was founded by Stig Ollmar, Associate Professor at The
Karolinska Institute in Stockholm, Sweden. Nevisense is based on
substantial research and has achieved excellent results in the largest
clinical study ever conducted on the detection of malignant melanoma.
Nevisense is CE marked in Europe, has TGA approval in Australia, and is
awaiting FDA clearance in the United States. Nevisense is based on a
method called Electrical Impedance Spectroscopy (EIS), which uses the
varying electrical properties of human tissue to categorize cellular
structures and thereby detect malignancies. SciBase is listed on Nasdaq
First North (“SCIB”). Avanza is the certified advisor. Further
information is available on www.scibase.com.
This information was brought to you by Cision http://news.cision.com